BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee MW, Kang D, Lim HK, Cho J, Sinn DH, Kang TW, Song KD, Rhim H, Cha DI, Lu DSK. Updated 10-year outcomes of percutaneous radiofrequency ablation as first-line therapy for single hepatocellular carcinoma < 3 cm: emphasis on association of local tumor progression and overall survival. Eur Radiol 2020;30:2391-400. [DOI: 10.1007/s00330-019-06575-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Gupta P, Kalra N, Chaluvashetty SB, Gamangatti S, Mukund A, Abdul R, Shyam V, Baijal SS, Mohan C. Indian College of Radiology and Imaging Guidelines on Interventions in Hepatocellular Carcinoma. Indian J Radiol Imaging. [DOI: 10.1055/s-0042-1754361] [Reference Citation Analysis]
2 Xie Q, Yang Y, Qu B, Xiao P, Tang F, Shen H. Comparison of surgical resection and radiofrequency ablation for stages I and II elderly hepatocellular carcinoma patients (≥ 65 years): A SEER population-based propensity score matching’s study. Front Oncol 2022;12:903231. [DOI: 10.3389/fonc.2022.903231] [Reference Citation Analysis]
3 Nakai M, Morikawa K, Hosoda S, Yoshida S, Kubo A, Tokuchi Y, Kitagataya T, Yamada R, Ohara M, Sho T, Suda G, Ogawa K, Sakamoto N. Pre-sarcopenia and Mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinoma. World J Hepatol 2022; 14(7): 1480-1494 [DOI: 10.4254/wjh.v14.i7.1480] [Reference Citation Analysis]
4 Tian Z, Hong B, Chen J, Tang Z. Combination of Radiofrequency Ablation With Resiquimod to Treat Hepatocellular Carcinoma Via Inflammation of Tumor Immune Microenvironment and Suppression of Angiogenesis. Front Oncol 2022;12:891724. [PMID: 35719978 DOI: 10.3389/fonc.2022.891724] [Reference Citation Analysis]
5 Long H, Xie X, Huang G, Huang T, Xie X, Liu B. Prognostic Role of Albumin-Bilirubin Grade in Hepatocellular Carcinoma After Ultrasound-guided Percutaneous Radiofrequency Ablation: A Single-center Experience Over a Decade. Surg Laparosc Endosc Percutan Tech 2022;32:350-6. [PMID: 35297807 DOI: 10.1097/SLE.0000000000001049] [Reference Citation Analysis]
6 Zane KE, Nagib PB, Jalil S, Mumtaz K, Makary MS. Emerging curative-intent minimally-invasive therapies for hepatocellular carcinoma. World J Hepatol 2022; 14(5): 885-895 [DOI: 10.4254/wjh.v14.i5.885] [Reference Citation Analysis]
7 Fang Z, Wei H, Zhang H, Moser MAJ, Zhang W, Qian Z, Zhang B. Radiofrequency ablation for liver tumors abutting complex blood vessel structures: treatment protocol optimization using response surface method and computer modeling. Int J Hyperthermia 2022;39:733-42. [PMID: 35610101 DOI: 10.1080/02656736.2022.2075567] [Reference Citation Analysis]
8 Li S, Zhu C, Zhou X, Chen L, Bo X, Shen Y, Guan X, Han X, Shan D, Sun L, Chen Y, Xu H, Yue W. Engineering ROS-Responsive Bioscaffolds for Disrupting Myeloid Cell-Driven Immunosuppressive Niche to Enhance PD-L1 Blockade-Based Postablative Immunotherapy. Adv Sci (Weinh) 2022;9:e2104619. [PMID: 35156339 DOI: 10.1002/advs.202104619] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Kwak MH, Lee MW, Ko SE, Rhim H, Kang TW, Song KD, Kim JM, Choi GS. Laparoscopic radiofrequency ablation versus percutaneous radiofrequency ablation for subphrenic hepatocellular carcinoma. Ultrasonography 2022. [PMID: 35430787 DOI: 10.14366/usg.21241] [Reference Citation Analysis]
10 Lim S, Shin Y, Lee YH. Arterial enhancing local tumor progression detection on CT images using convolutional neural network after hepatocellular carcinoma ablation: a preliminary study. Sci Rep 2022;12:1754. [PMID: 35110631 DOI: 10.1038/s41598-022-05794-8] [Reference Citation Analysis]
11 Cao S, Lyu T, Fan Z, Guan H, Song L, Tong X, Wang J, Zou Y. Long-term outcome of percutaneous radiofrequency ablation for periportal hepatocellular carcinoma: tumor recurrence or progression, survival and clinical significance. Cancer Imaging 2022;22:2. [PMID: 34983650 DOI: 10.1186/s40644-021-00442-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Tan J, Mathy RM, Chang DH, Tang T, Zhang ZS, Xiao YD. Combined transarterial iodized oil injection and computed tomography-guided thermal ablation for hepatocellular carcinoma: utility of the iodized oil retention pattern. Abdom Radiol (NY) 2022;47:431-42. [PMID: 34642785 DOI: 10.1007/s00261-021-03305-3] [Reference Citation Analysis]
13 Cao S, Zou Y, Lyu T, Fan Z, Guan H, Song L, Tong X, Wang J. Long-term outcomes of combined transarterial chemoembolization and radiofrequency ablation versus RFA monotherapy for single hepatocellular carcinoma ≤3 cm: emphasis on local tumor progression. Int J Hyperthermia 2022;39:1-7. [PMID: 34937501 DOI: 10.1080/02656736.2021.1998660] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
14 Conci S, D'Onofrio M, Bianco A, Campagnaro T, Martone E, De Bellis M, Longo C, Dedoni S, Vittoria D'Addetta M, Ciangherotti A, Pedrazzani C, Dalbeni A, Campagnola P, Mansueto G, Guglielmi A, Ruzzenente A. Ablation Difficulty Score: Proposal of a new tool to predict success rate of percutaneous ablation for hepatocarcinoma. Eur J Radiol 2022;146:110097. [PMID: 34896959 DOI: 10.1016/j.ejrad.2021.110097] [Reference Citation Analysis]
15 Kim JG, Cho SK, Hyun D, Shin SW, Park KB, Park HS, Choo SW, Do YS, Woo SY, Baek SY. Combined transarterial chemoembolization and radiofrequency ablation for subphrenic versus nonsubphrenic hepatocellular carcinoma: a propensity score matched study. Abdom Radiol (NY) 2021;46:5735-45. [PMID: 34581928 DOI: 10.1007/s00261-021-03291-6] [Reference Citation Analysis]
16 Wang L, Xu J, Yu J, Liang P. Review of clinical tumor ablation advance in Asia. Int J Hyperthermia 2021;38:1639-49. [PMID: 34781824 DOI: 10.1080/02656736.2021.1983037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Bo XW, Sun LP, Yu SY, Xu HX. Thermal ablation and immunotherapy for hepatocellular carcinoma: Recent advances and future directions. World J Gastrointest Oncol 2021; 13(10): 1397-1411 [PMID: 34721773 DOI: 10.4251/wjgo.v13.i10.1397] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
18 Bai XM, Yang W. Radiofrequency ablation of hepatocellular carcinoma: Prognostic factors and recent advances. Shijie Huaren Xiaohua Zazhi 2021; 29(13): 677-683 [DOI: 10.11569/wcjd.v29.i13.677] [Reference Citation Analysis]
19 Solbiati L, Ierace T, Gennaro N, Muglia R, Cosman ER Jr, Goldberg SN. Percutaneous radiofrequency ablation of HCC: reduced ablation duration and increased ablation size using single, internally cooled electrodes with an optimized pulsing algorithm. Int J Hyperthermia 2020;37:861-7. [PMID: 32669003 DOI: 10.1080/02656736.2020.1790678] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Huang J, Huang W, Guo Y, Cai M, Zhou J, Lin L, Zhu K. Risk Factors, Patterns, and Long-Term Survival of Recurrence After Radiofrequency Ablation With or Without Transarterial Chemoembolization for Hepatocellular Carcinoma. Front Oncol 2021;11:638428. [PMID: 34123790 DOI: 10.3389/fonc.2021.638428] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
21 Lin CC, Lui KW, Chen WT, Hsieh YC, Cheng YT, Teng W, Lin SM. Switching monopolar radiofrequency ablation improves long-term outcomes of medium-sized hepatocellular carcinoma. Eur Radiol 2021. [PMID: 33895858 DOI: 10.1007/s00330-021-07729-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Park SJ, Cho EJ, Lee JH, Yu SJ, Kim YJ, Yoon JH, Kang HJ, Yoon JH, Lee DH, Kim SH, Lee JY, Lee JM. Switching Monopolar No-Touch Radiofrequency Ablation Using Octopus Electrodes for Small Hepatocellular Carcinoma: A Randomized Clinical Trial. Liver Cancer 2021;10:72-81. [PMID: 33708641 DOI: 10.1159/000512338] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
23 Song BG, Kim MJ, Sinn DH, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. A comparison of factors associated with the temporal improvement in the overall survival of BCLC stage 0 hepatocellular carcinoma patients. Dig Liver Dis 2021;53:210-5. [PMID: 33189588 DOI: 10.1016/j.dld.2020.10.030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Defreyne L. Interventional radiology for liver diseases. Eur Radiol 2021;31:2227-30. [PMID: 33009937 DOI: 10.1007/s00330-020-07356-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
25 Long H, Zhuang B, Huang G, Li X, Lin M, Long J, Xie X, Liu B. Safety and Local Efficacy of Laser Ablation for the Extrahepatic Metastasis of Hepatocellular Carcinoma: An Available Treatment Strategy. Coatings 2020;10:951. [DOI: 10.3390/coatings10100951] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Han X, Dong J, Liu Z, Wu B, Tian Y, Tan H, Cheng W. Quantitative dynamic contrast-enhanced ultrasound to predict intrahepatic recurrence of hepatocellular carcinoma after radiofrequency ablation: a cohort study. International Journal of Hyperthermia 2020;37:1066-73. [DOI: 10.1080/02656736.2020.1817576] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
27 Ho P, Teng W, Lin C, Jeng W, Chen W, Lin C, Lin S, Sheen I. Prolonged post-ablation fever may predict one-year tumor recurrence in hepatocellular carcinoma after radiofrequency ablation. International Journal of Hyperthermia 2020;37:1008-15. [DOI: 10.1080/02656736.2020.1806363] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
28 Gupta P, Kalra N, Keshava SN, Chaluvashetty SB, Mukund A, Roy-choudhury SH, Baijal SS, Khandelwal A, Ananthashayana VH, R. SN, Kulkarni S, Shetty NS, Gupta A, Gupta S. Indian Society of Vascular and Interventional Radiology Expert Consensus Statements for Ablation in Hepatocellular Carcinoma: Part I. Journal of Clinical Interventional Radiology ISVIR 2020;4:098-106. [DOI: 10.1055/s-0040-1715774] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
29 Mizandari M, Azrumelashvili T, Toria N, Nanava N, Pantsulaia I, Kikodze N, Janikashvili N, Chikovani T. Cured giant hepatocellular carcinoma after transarterial embolization complicated with liver abscess formation. Radiol Case Rep 2020;15:1485-92. [PMID: 32670446 DOI: 10.1016/j.radcr.2020.06.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Santambrogio R, Barabino M, De Nicola E, Galfrascoli E, Giovenzana M, Zappa MA. Laparoscopic ablation therapies for hepatocellular carcinoma: could specific indications for the laparoscopic approach influence the effectiveness? Updates Surg 2020;72:435-43. [DOI: 10.1007/s13304-020-00759-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]